Brief: Inventiva End-June Cash Position At EUR 87.2 Mln

Inventiva SA

29/07/2022 07:35

July 29 (Reuters) - Inventiva  IVAA.PA :
    * REPORTED ON THURSDAY CASH POSITION AT €87.2 M AS OF JUNE
30,
2022
    * REVENUES OF €0.1 M IN H1 2022
    * ENTERED INTO A FINANCE LOAN AND A WARRANT AGREEMENT FOR UP
TO
€50 MILLION WITH THE EUROPEAN INVESTMENT BANK (EIB)
    * CASH RUNWAY EXTENDED UNTIL THE END OF SECOND QUARTER 2023
WITHOUT TAKING INTO ACCOUNT THE €50M FINANCE LOAN FROM THE EIB
    * STRATEGY UPDATE ON THE POTENTIAL DEVELOPMENT OF ODIPARCIL
–
ANTICIPATED BY END OF 2022
    * PUBLICATION OF RESULTS OF INVESTIGATOR-INITIATED STUDY
WITH
LANIFIBRANOR IN PATIENTS WITH NAFLD AND T2D IS NOW EXPECTED IN
THE FIRST QUARTER OF 2023
    * LAST PATIENT FIRST VISIT OF THE NATIV3 PHASE III CLINICAL
TRIAL
EVALUATING LANIFIBRANOR IN NASH – PLANNED FOR FIRST HALF OF 2023
    * STUDY COMPLETION OF PHASE IIB TRIAL OF CEDIROGANT IN
PATIENT
WITH PSORIASIS CONDUCTED BY ABBVIE – PLANNED FOR FIRST HALF OF
2023
    * TOPLINE RESULTS OF PHASE IIA LEGEND OF LANIFIBRANOR IN
COMBINATION WITH EMPAGLIFLOZIN IN PATIENTS WITH NASH AND T2D–
PLANNED FOR SECOND HALF OF 2023

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE97SDJ3
 Further company coverage:  IVAA.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))